Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Topimac, Tapiristat, Toxur, Topiroxo, Topiloric, Uriadec
Synonyms :
topiroxostat
Class :
Xanthine oxidase inhibitor/Non-purine agent
Brand Name :
Topimac, Tapiristat, Toxur, Topiroxo, Topiloric, Uriadec
Synonyms :
topiroxostat
Class :
Xanthine oxidase inhibitor/Non-purine agent
Dosage Forms & StrengthsÂ
TabletÂ
20mgÂ
40mgÂ
60mgÂ
Initial dose: 20mg orally twice daily
Maintenance dose: 60mg orally twice a day
Maximum dose: 80mg orally twice a day
Initial dose: 20mg orally twice daily:
Maintenance dose: 60mg orally twice a day
Maximum dose: 80mg orally twice a day
Safety and efficacy study data is not available
Refer to adult dosing
the rate of excretion of topiroxostat may be reduced
the serum levels of abemaciclib may be increased
the serum levels of acalabrutinib may be increased
the rate of excretion of topiroxostat may be reduced
the rate of excretion of topiroxostat may be increased
the rate of excretion of acrivastine may be reduced
the rate of metabolism of alprazolam may be reduced
the rate of metabolism of amprenavir may be reduced
the rate of metabolism of anastrozole may be reduced
the rate of excretion of topiroxostat may be reduced
the serum levels of belzutifan may be increased
the rate of excretion of bepotastine may be reduced
the rate of excretion of topiroxostat may be reduced
the serum levels of bortezomib may be increased
Actions and spectrum:Â
The production of uric acid is blocked by topiroxostat as it inhibits the activity of the xanthine oxidase enzyme, which is responsible for the formation of uric acid
Frequency not definedÂ
Stomach upsetÂ
DrowsinessÂ
Headache Â
Increased level of enzymes in the liverÂ
Do not administer topiroxostat if allergic to the medication.
Contraindication/Caution:Â
Contraindication:Â
HypersensitivityÂ
Cardiac disordersÂ
Caution:Â
Heart attackÂ
Chest painÂ
Breathing difficultiesÂ
Severe or sudden headache
Pregnancy consideration:Â Â
USFDA pregnancy category: Safety data is not availableÂ
Lactation:Â Â
The data about the excretion of topiroxostat into breast milk is not knownÂ
Pregnancy category:Â Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.Â
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â
Topiroxostat is a non-purine inhibitor of the xanthine oxidase enzymeÂ
Â
Pharmacodynamics:Â
Through time-dependent and selective competitive inhibition of xanthine oxidase, topiroxostat lowers the production of uric acid. It lowers the amount of uric acid and insoluble urates in plasma, tissues, and urine.Â
Pharmacokinetics:Â
Â
AbsorptionÂ
Peak plasma concentration: 229.9ng/mlÂ
Time to reach peak plasma concentration: 0.67 hoursÂ
DistributionÂ
The volume of distribution is found to be around 6.7% to 12.8%. More than 97.5% of the drug is protein-boundÂ
MetabolismÂ
Topiroxostat is metabolized in the liver by glucuronidation, which inactivates it. The hydroxide and N-oxide metabolites of topiroxostat are found to be pyridine 2 (or 6)- hydroxide and pyridine N-oxide, respectively Â
Elimination and excretionÂ
40.9% of the drug is eliminated through feces, whereas 30.4% is eliminated through urineÂ
Half-life:Â
The mean half-life under the fasting state is 5 hours
Administration:Â
Topiroxostat should be administered orally after meals
Patient information leafletÂ
Generic Name: topiroxostatÂ
Why do we use topiroxostat?Â
Topiroxostat is used in the management and treatment of hyperuricemia and gout. It is a selective inhibitor of xanthine oxidase enzyme.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
